After stratification of patients according to the etiology of liver disease (ALD&NAFLD vs. others), homozygosity for PNPLA3 148M was associated with lower survival in ALD&NAFLD (p = 0.003 at Log-Rank test; median survival 30, 95% c.i. 20–39 vs. 45, 95% c.i. 38–52 months; Figure 3A), but not in patients with other etiologies (p = 0.86 at Log-Rank test; median survival 48, 95% c.i. 32–64 vs. 55, 95% c.i. 43–67 months; Figure 3B). This evidence concerns the gene PNPLA3 and liver disorder.